# NCT02933255 (NCT02933255)

> PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer

No report yet. It can be ordered.

- Indication: prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02933255
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: National Cancer Institute (NCI)
- Conditions: Prostate Cancer
- Interventions: PROSTVAC-V/F; Nivolumab; Prostatectomy; Biopsy; Tylenol
- Enrollment: 24
- Primary outcome: Number of Participants With Clinically Important Immune-related Adverse Events (for the Lead-In Cohort)
- Primary outcome: Changes in T-cell Infiltration in the Tumor After Neoadjuvant Treatment (Only for the Neoadjuvant Cohort)

## Indexed commentary on NCT02933255 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02933255